Navigation Links
Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
Date:9/4/2013

MALVERN, Pa. and RALEIGH, N.C., Sept. 4, 2013 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), and BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine. 

The interim analyses were conducted as part of the Phase III protocol to allow for adjustments to the sample size in order to maintain appropriate study power to detect statistically significant differences between BEMA Buprenorphine and placebo.  The analyses were conducted by an independent biostatistician.

Endo and BDSI view the outcomes of the interim analyses as encouraging. As a result of the interim analyses, it was determined that no sample size adjustment will be necessary to the opioid naive study.  Additional patients will be added to the ongoing opioid experienced trial to maintain appropriate power to allow for the detection of a statistically significant difference between BEMA Buprenorphine and placebo based on the primary efficacy endpoint.

"We are encouraged by the outcomes of the interim analyses which were conducted to determine if the original sample size assumptions were appropriate and to allow for adjustments to the study sample size to preserve appropriate study power," stated Dr. Ivan Gergel, executive vice president of research & development at Endo.  "As a leader in the treatment of chronic pain we are excited about the potential for BEMA Buprenorphine as one of our lead development programs for our branded pharmaceuticals business."

"The outcomes of the interim analyses are sign
'/>"/>

SOURCE Endo Pharmaceuticals Inc.; BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
2. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
3. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
4. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
5. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
6. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
7. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
9. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
10. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its clinical ... has been very productive for CytRx. Enrollment in our ... in soft tissue sarcoma (STS) continues on track to ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, ... will host its Second Quarter 2015 Investor Conference Call ...    The call will cover an update ... second quarter 2015 financials. A press release detailing the ... issued the afternoon of Monday, August 10. Investors and ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... Northwestern Memorial Hospital is one of six national participants ... lung cancer patients and their families have a smoother ... to reduce medical error and to reliably adhere to ... Commission on Cancer and the Society of Thoracic Surgeons ...
... PRUSSIA, Pa., Nov. 18, 2010  Prism ... & Drug Administration (FDA) has approved the supplemental ... Injection, the first and only premixed intravenous (IV) ...  NEXTERONE Premixed Injection is indicated for initiation of ...
Cached Medicine Technology:Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 2Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 3
(Date:8/3/2015)... ... , ... They know every second counts. And when it comes to stroke, ... the best care in the nation. For the past two months, the stroke team ... removal time in the country. During the months of June and July, it took ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the ... to offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists ... , Annually, more than 8.6 million adverse drug events are reported in the ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... and fitness site and the largest online retailer of nutritional supplements, has ... Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2
... tips on controlling your flatulence , ... East Longmeadow, ... necessary. In fact, the average person passes gas about 14 times ... However, every body behaves differently and some experience more gas than ...
... Robert Bernstein, developer of the Follicular Unit Transplantation procedure for ... hair loss and its treatment. , ... ... The Oprah Winfrey Show features Dr. Bernstein discussing his pioneering ...
... previously published ACSM/AHA, guidelines, INDIANAPOLIS ... activity released today by the U.S. Department ... with support from the American College of,Sports ... (AHA). The,organizations, which jointly published physical activity ...
... ANAHEIM, Calif., Oct. 7 CHADD, ... by AD/HD, will hold its Annual,International ... Anaheim, California.,The conference will feature some ... variety,topics of interest to parents, adults, ...
... similar to more expensive whole-leg color ultrasound, study ... older, simpler test to look for blood clots in ... -- is as effective as a newer, more expensive ... 2-point ultrasonography of the leg -- sometimes called compression ...
... the University of California, San Diego (UCSD) in La Jolla ... lung cancer by treating patients with a novel kind of ... immune system to fight off a cancer, the new vaccine, ... turning off its immune system-suppressing activities. , The first patients ...
Cached Medicine News:Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Pioneering Hair Transplant Doctor Explains Procedure on Oprah Winfrey Show 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
... AccuGENE Molecular Biology Buffers are ready-to-use ... molecular biology applications. Each reagent is prepared ... 0.2 micron filter, and filled into sterile ... strict quality control standards to ensure lot-to-lot ...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
Medicine Products: